New myasthenia gravis therapies
FcRn blockers and complement inhibitors in myasthenia gravis.
Key point
Terminal complement pathway inhibitors and neonatal Fc receptor antagonists are reshaping myasthenia gravis treatment, with robust evidence of efficacy and safety.
From: Portuguese Consensus Guidelines for the Diagnosis and Treatment of Myasthenia Gravis (Acta Med Port, 2026 Jan 2) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 4, 5, 16, 19, 19.
New guidelines and consensus this year
- Portuguese Consensus Guidelines for the Diagnosis and Treatment of Myasthenia GravisActa Med Port2026 Jan 2
All papers from the last 12 months
246 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Anti-C2-mediated complement inhibition prevents disease in a rat passive transfer model of myasthenia gravisJ Transl Autoimmun2026 DecPMID 42564559
- Terminal complement inhibition is associated with renal, hematologic, and thrombotic complications during septic shock: A global propensity score-matched cohort studyJ Crit Care2026 DecPMID 42526359
- Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trialsHum Vaccin Immunother2026 DecPMID 42084498
- Immune checkpoint inhibitor-induced myocarditis with myositis and/or myasthenia gravis overlap syndrome: A case seriesExp Ther Med2026 NovPMID 42840483
- Rozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia GravisCNS Drugs2026 NovPMID 42814271Review
- Perioperative Administration of Efgartigimod in myasthenia gravis patients with Thymoma: A six-case seriesJ Neuroimmunol2026 NovPMID 42462363
- The Expanding Therapeutic Landscape in Myasthenia GravisMuscle Nerve2026 Oct 12PMID 42865028
- A potential biomarker for the efficacy of complement inhibitors in myasthenia gravisJ Neurol Sci2026 Oct 10PMID 42868840
- Safety of Ravulizumab Use in Pregnancy: Insights from a Global Pharmacovigilance AnalysisAdv Ther2026 Oct 9PMID 42853533
- Real-world Treatment Patterns Among Patients with Generalized Myasthenia Gravis in the United StatesNeurol Ther2026 Oct 6PMID 42839213
More neurology trends
All specialties →Tenecteplase in stroke
Tenecteplase as the thrombolytic for acute ischaemic stroke.
Key point: Intravenous tenecteplase before thrombectomy showed benefit in ASPECTS <8, but no functional improvement and possible safety concerns in ASPECTS 8-10.
Post-stroke dysphagia
Studies of swallowing disorders after stroke and their treatment, including neuromodulation.
Anti-amyloid antibodies
Lecanemab, donanemab and related antibodies for early Alzheimer's disease.
Wearable seizure detection
Wearable devices and algorithms to detect or forecast seizures.
Autoimmune encephalitis
Antibody-mediated encephalitis, its diagnosis and treatment.
Brain-computer interfaces
Devices that translate brain signals into control of computers or limbs.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"myasthenia gravis"[tiab] AND (efgartigimod[tiab] OR rozanolixizumab[tiab] OR FcRn[tiab] OR complement[tiab] OR zilucoplan[tiab] OR ravulizumab[tiab] OR eculizumab[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.